Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. - Wikidata - awgldk - TriplyDB

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

http://www.wikidata.org/entity/Q46344305

about

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline Phosphate control in dialysis Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study Trends in the incidence of intestinal perforation in US dialysis patients (1992-2005).Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials.Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: A case report Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.Vascular and valvular calcification in chronic peritoneal dialysis patients.Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.Next-generation phosphate binders: focus on iron-based binders.Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.Advances in pharmacotherapy for secondary hyperparathyroidism.The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects

P2860

Q24234036-23870883-6896-4680-BA73-F0EEFCD31EE7 Q26866391-D24D4D98-38D2-48B8-99A3-51380BC75EC2 Q27025339-2888A827-759C-4C07-BD9D-8A35344958CF Q28535870-AFE081B7-9F9B-4902-B3FD-859F134470B4 Q33980629-4332C1FB-B78A-4926-8021-C57902F31536 Q34213692-A025A9D2-0E09-4C59-A3BC-D8F783D25798 Q34505136-DA054D4A-E807-498C-9F93-13CA942634DC Q34885173-2ABA8C95-9486-40BA-8A5A-71E61E579882 Q35730847-332B92DD-12A5-41F5-93D9-7F6586A12134 Q36443804-C2F8D8F2-862B-4DF9-8FB9-D2A353661071 Q37171642-FB84E592-55DB-459A-856D-F8979BF2BD4F Q37567574-4877F62B-F094-46F2-85D3-9DFCC5C6DA3A Q37914009-AF1234CC-F8EF-43B7-AB95-CEE3738252DB Q38202179-E8A901A3-C216-4159-B91A-BA9C9B93452C Q38213502-3F31B1CD-2C49-4364-B49F-2B81D88ED728 Q38219038-85607821-BA28-474B-A84A-D44DEC2A86A5 Q38229088-8B2D0D90-A1AE-4001-9085-B80B2A7618A5 Q38544533-EAA69F4A-557E-4D55-B7B4-9E8DA527695C Q38819231-4F1D7A3F-21B3-4083-8260-72A359059006 Q39220825-9A4840D3-3154-4E94-815D-06EFF9636A2D Q43427754-59158B14-6F15-4286-A219-0E79B16B05A2 Q44853372-BCFA215B-68EF-45B9-A564-292E61594311 Q49846193-DAFD411F-15CD-43B3-B68C-195E54F5F15A Q57219101-5E99023E-CB94-48B3-B147-174A90537B83

P2860

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

http://www.wikidata.org/entity/Q46344305

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@en

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@nl

type

label

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@en

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@nl

prefLabel

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@en

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@nl

P1433

Q46344305-3D0A0474-6F5F-416B-8C1A-3060E06B5FE5

P1476

Q46344305-60388B58-FB7A-4E27-BF10-79071FD78144

P2093

Q46344305-4806E3A4-CCB5-490A-92B0-B65FDB480B81

Q46344305-58BBC293-D9FE-4508-A3EB-CC6299BFB319

Q46344305-61F4606D-4235-4AE2-9201-7C55130B60CE

Q46344305-6DF9928F-1FD2-4AC8-A187-E14CEB3DECDD

Q46344305-85C90A77-7A2B-44DA-B454-971284527622

Q46344305-A3CDB7CD-C3CE-4CDB-9F0B-24300E85343C

Q46344305-AC694C14-1F7E-48A4-B96B-48A136A422FE

Q46344305-AD5891A0-26B6-448B-B2C1-76D65FD9FDC4

Q46344305-E91A2BA1-C211-4B69-A099-9F405FEC97F7

P2860

Q46344305-07DF6685-8EF3-4538-902F-5A37A70C90B1

Q46344305-201D2E1E-5559-43F5-9461-81961054A7E0

Q46344305-22E8EDE5-2D89-4D4A-89DA-5D14041AB029

Q46344305-2D07408C-04FB-491B-99B9-FDA67FBE294D

Q46344305-2F3A6B5E-9E82-4E22-A412-F51282AA0350

Q46344305-3541F137-62FC-4611-BF13-573F13786228

Q46344305-390E04D6-9ED2-47BF-87B2-D61BBE41DD4B

Q46344305-50AECD6C-05C7-4CFE-B53C-EDF0D2670B14

Q46344305-55F31B25-B0D8-4577-B541-C1CD7AF7C809

Q46344305-7F5635D6-CC7D-41C8-B05E-3978096267FA

P304

Q46344305-C893B888-0540-4CB6-A1BF-08ED3DA65F83

P31

Q46344305-8AB9283E-EE32-458F-AB43-DBCCD9894058

P356

Q46344305-0B90579C-2378-4A7E-90FC-4F7C0AFB79F9

P407

Q46344305-5F3191E7-AD22-40C7-8BA8-BED820E088F9

P433

Q46344305-809A9E69-BA7F-48DB-BE0D-5105EA81E35E

P478

Q46344305-46D62651-3100-48B5-8512-EB6FE98059EE

P50

Q46344305-C161735B-96BC-4DF4-8DC3-46E019838DFF

P577

Q46344305-D46E19B2-93E5-4B56-84BE-B2DBA4B33D78

P5875

Q46344305-4FC16D91-2BCA-4C96-94F1-E85620522D87

P698

Q46344305-03BFD075-A8EE-4F8D-88EB-2AD6F1D3F0DE

P921

Q46344305-74995A1A-A5CC-4A8C-BF90-416A8A5FBDAC

P356

P1433

Nephrology Dialysis Transplantation

P1476

Efficacy and safety of sevelam ...... tients on peritoneal dialysis.

@en

P2093

Ajay Duggal

http://www.w3.org/2001/XMLSchema#string

Alison Kelly

http://www.w3.org/2001/XMLSchema#string

Flavia Caputo

http://www.w3.org/2001/XMLSchema#string

James G Heaf

http://www.w3.org/2001/XMLSchema#string

Lukas Foggensteiner

http://www.w3.org/2001/XMLSchema#string

Pieter Evenepoel

http://www.w3.org/2001/XMLSchema#string

Rafael Selgas

http://www.w3.org/2001/XMLSchema#string

Scott Chasan-Taber

http://www.w3.org/2001/XMLSchema#string

Stanley Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial

The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?

The importance of residual renal function in dialysis patients.

Peritoneal and hemodialysis: I. Differences in patient characteristics at initiation.

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.

Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?

Arterial calcifications and bone histomorphometry in end-stage renal disease.

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

P304

278-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFN488

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23284341

http://www.w3.org/2001/XMLSchema#string

P698

18820280

http://www.w3.org/2001/XMLSchema#string

P921